Fashionable Eli Lilly (LLY) weight-loss drug Zepbound could be lined by Medicare plans to deal with sleep apnea after it obtained Food and Drug Administration (FDA) approval last month.

A Center for Medicare and Medicaid Services spokesperson advised Investopedia Thursday that «present Medicare Part D and Medicaid protection guidelines apply» to Zepbound, which means, it may be added to Half D plans and lined by Medicare. Hundreds of thousands of People are estimated to undergo from obstructive sleep apnea, a sleep problem.

Eli Lilly and Ozempic and Wegovy-maker Novo Nordisk (NVO) are testing their weight-loss medicine’ skills to deal with situations that usually accompany weight problems, similar to diabetes and sleep apnea. The change was first reported Wednesday by CNBC.

The drug can be lined by state-level Medicaid packages whether it is prescribed to deal with sleep apnea, and if the drug maker is a part of a Medicaid drug rebate program. About 780 firms take part within the rebate program, which covers medicine below Medicaid plans in alternate for the businesses paying rebates which might be cut up between states and the federal authorities to offset the price of the medicine.

Zepbound was accepted to deal with sleep apnea after clinical trials discovered that sufferers taking the drug with or without traditional sleep apnea remedies, like a masks, skilled a discount in respiratory interruptions throughout an evening of sleep.

The Biden administration in November proposed together with the load loss medicine in Medicare and Medicaid plans as a prescribed therapy for weight problems.